HCW Biologics Inc (HCWB)

Form 8-K - Current report

HCW Biologics Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026

Company completed 28 consecutive trading days above $1.00 per share on June 25, 2026 Reverse stock split...

Form EFFECT - Notice of Effectiveness

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

Form 8-K - Current report

HCW Biologics Announces Positive Results for Preliminary Human Data Readout for Phase 1 Clinical Trial Evaluating IL-2 Based Fusion Immunotherapeutic, HCW9302 Monotherapy, in Alopecia Areata

Potentially best-in-class IL-2 based treatment for autoimmune diseases by expanding and activating regulatory T...

Form 8-K - Current report

Form D - Notice of Exempt Offering of Securities

Form S-1 - General form for registration of securities under the Securities Act of 1933

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen

Positions the Company to participate in fast-growing, multi-billion-dollar CAR-T immunotherapy market Recently...

This Emerging Biotech Wave Could Create the Next Monster Healthcare Winners

DENVER, May 22, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – The biotechnology sector continues attracting speculative capital as...